Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azar Shahraz

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Theoretical Biology|April 1, 2021
A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancerHojjat Bazzazi, Azar Shahraz
Langmuir : the ACS Journal of Surfaces and Colloids|August 20, 2013
Wetting on physically patterned solid surfaces: the relevance of molecular dynamics simulations to macroscopic systemsAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Langmuir : the ACS Journal of Surfaces and Colloids|September 25, 2012
A theory for the morphological dependence of wetting on a physically patterned solid surfaceAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Langmuir : the ACS Journal of Surfaces and Colloids|December 4, 2014
Kinetics of droplet wetting mode transitions on grooved surfaces: forward flux samplingAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Clinical and Translational Science|December 26, 2025
Clinical Pharmacology Perspective on Direct-To-Subcutaneous Dosing of T Cell Engagers in Oncology First-In-Human StudiesWenlian Qiao, Azar Shahraz, Karthick Vishwanathan, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|June 2, 2015
Effects of Hierarchical Surface Roughness on Droplet Contact AngleMichael S Bell, Azar Shahraz, Kristen A Fichthorn, et al.
Clinical Pharmacology and Therapeutics|September 16, 2025
Reply to "High Pharmacokinetic Variability and Unrecognized Limitations in First-Line Osimertinib Plus Chemotherapy for EGFR-Mutated NSCLC"Azar Shahraz, Jincheng Yang, Diansong Zhou, et al.
Clinical Pharmacology and Therapeutics|July 10, 2025
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLCJincheng Yang, Damilola Olabode, Aarti Sawant-Basak, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2024
A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selectionAzar Shahraz, Mark Penney, Juliana Candido, et al.
Nucleic Acids Research|August 19, 2020
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugatesChristopher R Brown, Swati Gupta, June Qin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Theoretical Biology|April 1, 2021
A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancerHojjat Bazzazi, Azar Shahraz
Langmuir : the ACS Journal of Surfaces and Colloids|August 20, 2013
Wetting on physically patterned solid surfaces: the relevance of molecular dynamics simulations to macroscopic systemsAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Langmuir : the ACS Journal of Surfaces and Colloids|September 25, 2012
A theory for the morphological dependence of wetting on a physically patterned solid surfaceAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Langmuir : the ACS Journal of Surfaces and Colloids|December 4, 2014
Kinetics of droplet wetting mode transitions on grooved surfaces: forward flux samplingAzar Shahraz, Ali Borhan, Kristen A Fichthorn
Clinical and Translational Science|December 26, 2025
Clinical Pharmacology Perspective on Direct-To-Subcutaneous Dosing of T Cell Engagers in Oncology First-In-Human StudiesWenlian Qiao, Azar Shahraz, Karthick Vishwanathan, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|June 2, 2015
Effects of Hierarchical Surface Roughness on Droplet Contact AngleMichael S Bell, Azar Shahraz, Kristen A Fichthorn, et al.
Clinical Pharmacology and Therapeutics|September 16, 2025
Reply to "High Pharmacokinetic Variability and Unrecognized Limitations in First-Line Osimertinib Plus Chemotherapy for EGFR-Mutated NSCLC"Azar Shahraz, Jincheng Yang, Diansong Zhou, et al.
Clinical Pharmacology and Therapeutics|July 10, 2025
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLCJincheng Yang, Damilola Olabode, Aarti Sawant-Basak, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2024
A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selectionAzar Shahraz, Mark Penney, Juliana Candido, et al.
Nucleic Acids Research|August 19, 2020
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugatesChristopher R Brown, Swati Gupta, June Qin, et al.
Pageof 1